Accueil>>Signaling Pathways>> Others>>Acebilustat

Acebilustat (Synonyms: CTX-4430)

Catalog No.GC19018

Acebilustat (CTX-4430) est un inhibiteur de la leucotriène A4 hydrolase, utilisé pour un anti-inflammatoire oral.

Products are for research use only. Not for human use. We do not sell to patients.

Acebilustat Chemical Structure

Cas No.: 943764-99-6

Taille Prix Stock Qté
1mg
31,00 $US
En stock
5mg
99,00 $US
En stock
10mg
135,00 $US
En stock
25mg
270,00 $US
En stock
50mg
432,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Acebilustat is a leukotriene A4 hydrolase inhibitor, used for an oral antiinflammatory drug.

Acebilustat is a leukotriene A4 hydrolase inhibitor, which is safe and well tolerated in phase 1 trial[1]. Acebilustat is an antiinflammatory drug in development for the treatment of CF and other diseases. It is a potent inhibitor of the enzyme leukotriene A4 hydrolase (LTA4H), which catalyzes the rate-limiting step in the formation of leukotriene B4 (LTB4), a potent chemoattractant and activator of inflammatory immune cells including neutrophils[2].

References:
[1]. Elborn JS, et al. Phase 1 Studies of Acebilustat: Biomarker Response and Safety in Patients with Cystic Fibrosis. Clin Transl Sci. 2016 Nov 2.
[2]. Elborn JS, et al. Phase I Studies of Acebilustat: Pharmacokinetics, Pharmacodynamics, Food Effect, and CYP3A Induction. Clin Transl Sci. 2016 Oct 28.

Avis

Review for Acebilustat

Average Rating: 5 ★★★★★ (Based on Reviews and 22 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Acebilustat

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.